← Back to Search

Insulin

Insulin icodec for Type 2 Diabetes (ONWARDS 3 Trial)

Phase 3
Waitlist Available
Research Sponsored by Novo Nordisk A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from week 24 (p26) to week 26 (v28)
Awards & highlights

ONWARDS 3 Trial Summary

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)

Eligible Conditions
  • Type 2 Diabetes

ONWARDS 3 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from week 24 (p26) to week 26 (v28)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from week 24 (p26) to week 26 (v28) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in HbA1c (glycated haemoglobin)
Secondary outcome measures
Change in body weight
Change in fasting plasma glucose (FPG)
Insulin
+3 more

Side effects data

From 2020 Phase 2 trial • 247 Patients • NCT03751657
11%
Headache
8%
Nasopharyngitis
6%
Upper respiratory tract infection
1%
Lower limb fracture
1%
Metrorrhagia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Insulin 287
Insulin Glargine

ONWARDS 3 Trial Design

2Treatment groups
Experimental Treatment
Group I: Once weekly placebo and once daily insulin degludecExperimental Treatment2 Interventions
Participants will get once daily and once weekly injections
Group II: Once weekly insulin icodec + once daily placeboExperimental Treatment2 Interventions
Participants will get once daily and once weekly injections
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo insulin degludec
2021
Completed Phase 3
~590
Insulin icodec
2021
Completed Phase 3
~4120
Placebo insulin icodec
2021
Completed Phase 3
~590
Insulin degludec
2020
Completed Phase 4
~8720

Find a Location

Who is running the clinical trial?

Novo Nordisk A/SLead Sponsor
1,512 Previous Clinical Trials
2,387,441 Total Patients Enrolled
Clinical Transparency (dept. 1452)Study DirectorNovo Nordisk A/S
56 Previous Clinical Trials
44,532 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Texas
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Met criteria

How responsive is this trial?

Typically responds via
Email
Recent research and studies
clinicaltrials.govStudy
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)
2021. "A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04795531.
~147 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top